Anna Morelli

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

ROS1-rearranged Non–small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)

Rita Chiari, Biagio Ricciuti, Lorenza Landi et al. · Clinical Lung Cancer · 2019 · 100 citations

Medicine, Oncology, Cancer Genetics +15

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · Blood · 2020 · 20 citations

Medicine, Hematology, Oncology +17

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

Enrica Capelletto, Maria Rita Migliorino, Alessandro Morabito et al. · Lung Cancer · 2019 · 14 citations

Medicine, Oncology, Oncology Pharmacotherapy +5